Composition of Matter Patent and Translational Research Grant issued for ONC213

Composition of Matter Patent and Translational Research Grant issued for ONC213

Philadelphia, PA (April 30, 2019) – Oncoceutics, Inc. announced that the United States Patent and Trademark Office (USPTO) has issued patent #10,266,533 entitled “7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO [1,2-A]PYRIDO [3,4-E]PYRIMIDIN-5(1H)-ONE, ANALOGS THEREOF, AND SALTS THEREOF AND METHODS FOR THEIR USE IN THERAPY” with an expiration date of January 29, 2036. This patent covers the composition of matter for ONC213, its di-salt formulation, and its use in the treatment of cancer. In addition to the claims related to ONC213, the patent also contains claims for millions of structurally-related imipridones.
 
ONC213 is the fourth molecule in the company’s pipeline of “imipridone” family of anti-cancer small molecules that target G protein-coupled receptors, following ONC201, ONC206 and ONC212. As with other members of the imipridone class, ONC213 has very attractive chemical and biological properties including oral bioavailability, chemical stability and a large therapeutic index.
 
“We are delighted by the decision of the US Patent Office to grant Composition of Matter to the novel molecule ONC213,” said Martin Stogniew, Ph.D., Chief Development Officer of Oncoceutics. “This patent paves the way for future generations of imipridones to enter the clinic and eventually benefit the lives of patients.”

ONC213 has demonstrated anti-cancer activity and safety in various preclinical oncology models across hematological malignancies and solid tumors tested in the lab of Principal investigator Dr. Yubin Ge, Associate Professor of Oncology at the Karmanos Cancer Institute and Wayne State University School of Medicine. Results presented at the 61st American Society of Hematology Annual Meeting demonstrated that ONC213 targets leukemic stem cells in patient-derived xenograft mouse models, is well tolerated and combines synergistically with Bcl-2 inhibitor Venetoclax. Dr. Ge recently received a grant from the Kids Without Cancer and the Children’s Hospital of Michigan Foundation to further determine the mechanism of action of ONC213 and enable biomarker selection for clinical studies. 

“Our team at the Karmanos Cancer Institute is excited by the potential of ONC213 as a new type of cancer therapy,” said Dr. Yubin Ge. “We look forward to continuing development of this novel agent as it makes its way towards the clinic.”
 
About Oncoceutics
Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class of compounds, i.e. the “imipridones,” that selectively target G protein-coupled receptors for oncology. The first lead compound to emerge from this program is ONC201, an orally active small molecule DRD2 antagonist. The company is supported by grants from NCI, FDA, Musella Foundation, XCures, Cancer Commons, and a series of private and public partnerships.
 
Visit Oncoceutics more information.
 
About Kids Without Cancer
Founded as Leukemia, Research, Life (LRL) in 1981 and renamed Kids Without Cancer in 2011, this organization has, for the past 36 years, been raising money to fund the pediatric cancer research being conducted at Children’s Hospital of Michigan and its affiliates Wayne State University and the Karmanos Cancer Institute. Kids Without Cancer is the largest contributor of funds to pediatric cancer research at Children’s Hospital of all charities solely dedicated to funding cancer research.